TYRA
Tyra Biosciences, Inc.
Biotechnology
Market Cap$1.77B
5Y Perf.+87.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TYRA vs ERAS
Revenue, margins, valuation, and 5-year total return — side by side.
ERAS
Erasca, Inc.
Biotechnology
Market Cap$2.95B
5Y Perf.-51.0%
TYRA vs ERAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TYRA | ERAS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.77B | $2.95B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-120M | $-128M |
| Total Debt | $6M | $52M |
| Cash & Equiv. | $77M | $68M |
TYRA vs ERAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TYRA
ERAS
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Tyra Biosciences, I… (TYRA) | 100 | 187.0 | +87.0% |
| Erasca, Inc. (ERAS) | 100 | 49.0 | -51.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TYRA vs ERAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ERAS leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Tyra Biosciences, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TYRA
Tyra Biosciences, Inc.
The Income Pick
TYRA is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.75
- 26.5% 10Y total return vs ERAS's -40.3%
- Lower volatility, beta 0.75, Low D/E 2.2%, current ratio 14.67x
Best for: income & stability and long-term compounding
ERAS
Erasca, Inc.
The Growth Play
ERAS carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 16.9%
- 19.8% revenue growth vs TYRA's -38.9%
- +7.5% vs TYRA's +260.4%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ERAS | 19.8% revenue growth vs TYRA's -38.9% |
| Stability / Safety | TYRA | Beta 0.75 vs ERAS's 0.78, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ERAS | +7.5% vs TYRA's +260.4% |
| Efficiency (ROA) | ERAS | -30.4% ROA vs TYRA's -38.4%, ROIC -39.2% vs -44.8% |
TYRA vs ERAS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLERASLAGGINGTYRA
TYRATyra Biosciences, Inc.
1leads
ERASErasca, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs TYRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ERAS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ERAS5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ERAS4/6
Risk & VolatilityBeta, volatility, and downside exposure
TYRA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ERAS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TYRA and ERAS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | TYRATyra Biosciences,… | ERASErasca, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$132M | -$141M |
| Net IncomeAfter-tax profit | -$120M | -$128M |
| Free Cash FlowCash after capex | -$95M | -$98M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -32.6% | 0.0% |
ERAS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TYRA and ERAS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TYRATyra Biosciences,… | ERASErasca, Inc. |
|---|---|---|
| Market CapShares × price | $1.8B | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $2.9B |
| Trailing P/EPrice ÷ TTM EPS | -16.37x | -15.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 7.57x | 5.74x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TYRA and ERAS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ERAS leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ERAS delivers a -36.7% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-41 for TYRA. TYRA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ERAS's 0.12x. On the Piotroski fundamental quality scale (0–9), ERAS scores 2/9 vs TYRA's 1/9, reflecting mixed financial health.
| Metric | TYRATyra Biosciences,… | ERASErasca, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -41.2% | -36.7% |
| ROA (TTM)Return on assets | -38.4% | -30.4% |
| ROICReturn on invested capital | -44.8% | -39.2% |
| ROCEReturn on capital employed | -43.3% | -42.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.12x |
| Net DebtTotal debt minus cash | -$72M | -$16M |
| Cash & Equiv.Liquid assets | $77M | $68M |
| Total DebtShort + long-term debt | $6M | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ERAS leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ERAS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TYRA five years ago would be worth $12,654 today (with dividends reinvested), compared to $5,967 for ERAS. Over the past 12 months, ERAS leads with a +745.5% total return vs TYRA's +260.4%. The 3-year compound annual growth rate (CAGR) favors ERAS at 53.8% vs TYRA's 34.6% — a key indicator of consistent wealth creation.
| Metric | TYRATyra Biosciences,… | ERASErasca, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +22.8% | +189.7% |
| 1-Year ReturnPast 12 months | +260.4% | +745.5% |
| 3-Year ReturnCumulative with dividends | +143.7% | +263.6% |
| 5-Year ReturnCumulative with dividends | +26.5% | -40.3% |
| 10-Year ReturnCumulative with dividends | +26.5% | -40.3% |
| CAGR (3Y)Annualised 3-year return | +34.6% | +53.8% |
ERAS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
TYRA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TYRA is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than ERAS's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TYRA currently trades 80.9% from its 52-week high vs ERAS's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TYRATyra Biosciences,… | ERASErasca, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 0.78x |
| 52-Week HighHighest price in past year | $40.65 | $24.28 |
| 52-Week LowLowest price in past year | $8.75 | $1.06 |
| % of 52W HighCurrent price vs 52-week peak | +80.9% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 43.1 | 36.9 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 7.0M |
TYRA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TYRA as "Buy" and ERAS as "Buy". Consensus price targets imply 53.5% upside for TYRA (target: $51) vs 30.8% for ERAS (target: $14).
| Metric | TYRATyra Biosciences,… | ERASErasca, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $50.50 | $13.60 |
| # AnalystsCovering analysts | 7 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ERAS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TYRA leads in 1 (Risk & Volatility). 1 tied.
Best OverallErasca, Inc. (ERAS)Leads 3 of 6 categories
Loading custom metrics...
TYRA vs ERAS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TYRA or ERAS a better buy right now?
Analysts rate Tyra Biosciences, Inc.
(TYRA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TYRA or ERAS?
Over the past 5 years, Tyra Biosciences, Inc.
(TYRA) delivered a total return of +26. 5%, compared to -40. 3% for Erasca, Inc. (ERAS). Over 10 years, the gap is even starker: TYRA returned +26. 5% versus ERAS's -40. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TYRA or ERAS?
By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.
(TYRA) is the lower-risk stock at 0. 75β versus Erasca, Inc. 's 0. 78β — meaning ERAS is approximately 3% more volatile than TYRA relative to the S&P 500. On balance sheet safety, Tyra Biosciences, Inc. (TYRA) carries a lower debt/equity ratio of 2% versus 12% for Erasca, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TYRA or ERAS?
On earnings-per-share growth, the picture is similar: Erasca, Inc.
grew EPS 16. 9% year-over-year, compared to -33. 1% for Tyra Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TYRA or ERAS?
Tyra Biosciences, Inc.
(TYRA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Erasca, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TYRA leads at 0. 0% versus 0. 0% for ERAS. At the gross margin level — before operating expenses — TYRA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TYRA or ERAS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TYRA or ERAS better for a retirement portfolio?
For long-horizon retirement investors, Tyra Biosciences, Inc.
(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Both have compounded well over 10 years (TYRA: +26. 5%, ERAS: -40. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TYRA and ERAS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.